A modified melanoma-molGPA scoring model: assessment of survival after and efficacy of different radiotherapy modalities in patients with melanoma brain metastases

[1]  Quangang Zhu,et al.  Metabolism heterogeneity in melanoma fuels deactivation of immunotherapy: Predict before protect , 2022, Frontiers in Oncology.

[2]  M. Doroudian,et al.  Mesenchymal stem cell-derived exosomes as a new therapeutic strategy in the brain tumors , 2022, Stem cell research & therapy.

[3]  S. Patel,et al.  Targeting IRS-1/2 in Uveal Melanoma Inhibits In Vitro Cell Growth, Survival and Migration, and In Vivo Tumor Growth , 2022, bioRxiv.

[4]  V. Benites-Zapata,et al.  Lymphocyte-to-Monocyte Ratio and Clinical Outcomes in Cholangiocarcinoma: A Systematic Review and Meta-Analysis , 2022, Diagnostics.

[5]  Wen-Lun Wang,et al.  Prognostic significance of systemic inflammatory response markers in patients with superficial esophageal squamous cell carcinomas , 2022, Scientific Reports.

[6]  A. Crétu,et al.  Prognostic Factors of Low-Grade Gliomas in Adults , 2022, Current oncology.

[7]  K. Shannon,et al.  Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites , 2022, Journal for ImmunoTherapy of Cancer.

[8]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[9]  Hashem Younes,et al.  Melanoma brain metastases: is it time to eliminate radiotherapy? , 2020, Journal of Neuro-Oncology.

[10]  C. Anker,et al.  Changing Therapeutic Landscape for Melanoma With Multiple Brain Metastases. , 2020, Neurosurgery.

[11]  R. Scolyer,et al.  Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Wen Jiang,et al.  Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). , 2017, International journal of radiation oncology, biology, physics.

[13]  C. Oppenheim,et al.  Predictors of Outcome in Patients with Pediatric Intracerebral Hemorrhage: Development and Validation of a Modified Score. , 2017, Radiology.

[14]  J. Régis,et al.  Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery. , 2017, European journal of cancer.

[15]  S. Kennedy,et al.  Metastatic melanoma: prognostic factors and survival in patients with brain metastases , 2017, Journal of Neuro-Oncology.

[16]  M. Scorsetti,et al.  Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases? , 2016, Cancer treatment reviews.

[17]  D. Schadendorf,et al.  Systemic therapies for melanoma brain metastases: which drug for whom and when? , 2015, Chinese clinical oncology.

[18]  F. Hodi,et al.  The role of whole brain radiation therapy in the management of melanoma brain metastases , 2014, Radiation Oncology.

[19]  V. Sondak,et al.  Melanoma in the brain: biology and therapeutic options , 2012, Melanoma research.

[20]  P. Hwu,et al.  Prognostic factors for survival in melanoma patients with brain metastases , 2011, Cancer.

[21]  Hiroki Shirato,et al.  Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain Metastases: A Randomized Controlled Trial , 2007 .